SHL Telemedicine Ltd. Overview
Pro stress-test →SHL Telemedicine develops and markets advanced personal telemedicine solutions, operating as a leading telemedicine provider in Israel and Germany with vast experience in remote medical services, including 24/7 telemedicine centers with global services based on cloud technology. The company processes about 3 million medical interactions per year and specializes in remote cardiac care.
Strategic Profile
Pro stress-test →SHL's core offering is the SmartHeart platform, a 12-lead electrocardiogram (ECG) that enables a full, hospital-quality ECG to be performed by a lay-person without the assistance of a healthcare professional. The company has a collaboration agreement with Mayo Clinic to evaluate outcomes for heart attack patients using SmartHeart FDA approved 12 lead ECG. Geographically, Israeli operations account for about 77% of total revenues whilst the German business contributes 22%.
Competitive Landscape
Pro stress-test →SHL operates in a crowded telehealth market dominated by larger players like Teladoc Health and MDLive. However, SHL's differentiation lies in its focus on remote cardiac diagnostics—a specialized niche with fewer direct competitors. The company faces competition from traditional cardiac monitoring platforms and digital health generalists. Its Mayo Clinic partnership and FDA-cleared SmartHeart device provide defensible positioning for hospital and insurance company markets.
Industry Context
SHL Telemedicine Ltd. operates in Telemedicine / Remote Patient Monitoring / Health Information Services.
Key facts
Founded: 1986 · Headquarters: Tel Aviv, Israel · Employees: 526 · Revenue: $57M (FY2024) · Market cap: CHF 42.6M (December 2024)